Health Canada is alerting health care providers that sotrovimab, a COVID-19 monoclonal antibody therapy treatment, may no longer be effective against the BA.2 subvariant of Omicron.
that a COVID-19 monoclonal antibody therapy treatment may no longer be effective against the new subvariant of Omicron.
The agency reported on Thursday that sotrovimab, manufactured by GlaxoSmithKline and Vir Biotechnology, "is unlikely to maintain efficacy against the Omicron BA.2 subvariant," and said that the treatment exhibited "a reduction in activity" against the new subvariant. However, Health Canada says sotrovimab can still be administered to COVID-19 patients who test positive for the earlier subvariants of Omicron.
"Current data indicates that sotrovimab continues to be effective against the Omicron BA.1 and BA.1.1 subvariants," the agency said. "Local epidemiology and individual exposure to variants should be taken into consideration before use of sotrovimab."for treatment of mild to moderate cases of COVID-19 in adults and adolescents 12 years of age or older who are at a high risk of hospitalization or death.for the therapy due to rising cases of the BA.
Provincial health authorities have already been pulling or discouraging the treatment, instead recommending Paxlovid or Remdesivir.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nearly 1.5 million COVID-19 vaccine doses in national stockpile have expired since January: Health CanadaThere are more than 18 million COVID-19 vaccine doses in Canada’s national stockpile at the moment, the vast majority of which will expire in the next four months
Read more »
Health Canada approves AstraZeneca COVID-19 treatment for immunocompromised patients | CBC NewsHealth Canada has cleared an antibody-based therapy — Evusheld — for use in those unlikely to mount an adequate immune response to COVID-19 vaccination, or for whom COVID-19 vaccination is not recommended.
Read more »
Health Canada approves AstraZeneca’s COVID-19 drug to prevent infectionThe drug, named Evusheld, is intended for people who cannot receive a typical COVID-19 vaccine or for whom vaccines alone won’t provide enough immunity
Read more »
Health Canada greenlights AstraZeneca COVID-19 drug to prevent infectionHealth Canada has approved AstraZeneca's antibody combination to prevent symptomatic COVID-19 infection in immunocompromised people.
Read more »
Long COVID: The invisible public health crisis fuelling labour shortagesLong COVID is a disaster in the making for businesses and economies. Learn more here.
Read more »